Medulloblastoma (MB) is the most common malignant pediatric tumor, accounting for 15-20% of childhood brain tumors. Current multimodal therapies--including surgery and radiochemotherapy--increase long-term survival to 60-80%, but 33% of children diagnosed die in 5 years; the median survival for recurrent MB patients being less than 12 months. Molecular profiling and genetic analysis have categorized MB into 4 subgroups, each associated with distinct genetic alterations, age at onset, and prognosis.
